Author

Song Chen

National University of Singapore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Junsong Guo· 2 shared Ru‐Yi ZhuiD· 2 shared Tuan‐Khoa KhaiD· 2 shared Yiran ZhaoiD· 2 shared Aamir Dohadwala· 1 shared Adriana Roopnariane· 1 shared Arshi Arora· 1 shared Baixi CHEN· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Junsong Guo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Small Molecule-Directed RNA Modification via Proximity-Driven Catalysis

Song Chen, Tuan‐Khoa Kha, Yiran Zhao, Junsong Guo, Baixi CHEN, Ru‐Yi Zhu

This paper introduces a small molecule-directed method for site-selective RNA modification using DMAP catalysis and proximity-driven acylation, validated across multiple RNA types.

Journal of the American Chemical Society · Aug 18, 2026Peer-reviewedBiochemistry

Nitro Reduction-Based RNA Control and Ultrafast Release

Yiran Zhao, Senfeng Zhang, Junsong Guo, Tuan‐Khoa Kha, Song Chen, Chunyi Hu, Ru‐Yi Zhu

This paper introduces a reversible RNA modification strategy using nitro reduction to control RNA function and release, applicable across various RNA types and contexts.

Angewandte Chemie International Edition · Aug 5, 2026Peer-reviewedBiochemistry

KIF18A Inhibition as a Therapeutic Strategy in Cancers with Rb Pathway Inactivation

Celia Andreu, Arshi Arora, Song Chen, Chaithanya P. Vedula, Adriana Roopnariane, Sarah E. Bettigole, Nazario Bosco, Aamir Dohadwala, the SOVI-2302 Investigators, The VLS-1488-2201 Investigators, David Southwell, Neil J. Ganem, Timothy Geoffrey Bowler, Samuel F. W. Bakhoum

This paper identifies p16INK4a expression as a predictive biomarker for KIF18A inhibitor response in cancers with Rb pathway inactivation, showing higher response rates and longer progression-free survival in p16INK4a-high tumors.

bioRxiv · Apr 20, 2026 · PreprintCancer Biology